Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study

NCT01502982 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT01502982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01502982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study
Lead sponsor
Nordic Lymphoma Group
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
May 31, 2014
Enrollment
160 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma